Jazz Pharmaceuticals plc (JAZZ) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 4.60B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $4.60B | (m) | (m) |
| 2026-03-31 | (m) | $4.44B | (m) | (m) |
| 2025-12-31 | (m) | $4.27B | (m) | (m) |
| 2025-09-30 | (m) | $4.16B | (m) | (m) |
| 2025-06-30 | (m) | $4.09B | (m) | (m) |
| 2025-03-31 | (m) | $4.06B | (m) | (m) |
| 2024-12-31 | (m) | $4.07B | (m) | (m) |
| 2024-09-30 | (m) | $3.99B | (m) | (m) |
| 2024-06-30 | (m) | $3.91B | (m) | (m) |
| 2024-03-31 | (m) | $3.84B | (m) | (m) |
| 2023-12-31 | (m) | $3.83B | (m) | (m) |
| 2023-09-30 | (m) | $3.79B | (m) | (m) |
| 2023-06-30 | (m) | $3.76B | (m) | (m) |
| 2023-03-31 | (m) | $3.74B | (m) | (m) |
| 2022-12-31 | (m) | $3.66B | (m) | (m) |
| 2022-09-30 | (m) | $3.58B | (m) | (m) |
| 2022-06-30 | (m) | $3.48B | (m) | (m) |
| 2022-03-31 | (m) | $3.30B | (m) | (m) |
| 2021-12-31 | (m) | $3.09B | (m) | (m) |
| 2021-09-30 | (m) | $2.86B | (m) | (m) |
| 2021-06-30 | (m) | $2.63B | (m) | (m) |
| 2021-03-31 | (m) | $2.44B | (m) | (m) |
| 2020-12-31 | $2.20B | $2.36B | (m) | 92.98% |
| 2020-09-30 | (m) | $2.28B | (m) | (m) |
| 2020-06-30 | (m) | $2.22B | (m) | (m) |
| 2020-03-31 | (m) | $2.19B | (m) | (m) |
| 2019-12-31 | $2.01B | $2.16B | (m) | 92.87% |
| 2019-09-30 | (m) | $2.06B | (m) | (m) |
| 2019-06-30 | (m) | $1.99B | (m) | (m) |
| 2019-03-31 | (m) | $1.95B | (m) | (m) |
| 2018-12-31 | $1.75B | $1.89B | (m) | 92.44% |
| 2018-09-30 | (m) | $1.85B | (m) | (m) |
| 2018-06-30 | (m) | $1.79B | (m) | (m) |
| 2018-03-31 | (m) | $1.69B | (m) | (m) |
| 2017-12-31 | $1.49B | $1.62B | (m) | 92.12% |
| 2017-09-30 | (m) | $1.58B | (m) | (m) |
| 2017-06-30 | (m) | $1.54B | (m) | (m) |
| 2017-03-31 | (m) | $1.53B | (m) | (m) |
| 2016-12-31 | $1.37B | $1.49B | (m) | 92.20% |
| 2016-09-30 | (m) | $1.43B | (m) | (m) |
| 2016-06-30 | (m) | $1.40B | (m) | (m) |
| 2016-03-31 | (m) | $1.35B | (m) | (m) |
| 2015-12-31 | $1.21B | $1.32B | (m) | 91.66% |
| 2015-09-30 | (m) | $1.31B | (m) | (m) |
| 2015-06-30 | (m) | $1.28B | (m) | (m) |
| 2015-03-31 | (m) | $1.24B | (m) | (m) |
| 2014-12-31 | $1.05B | $1.17B | (m) | 89.12% |
| 2014-09-30 | (m) | $1.08B | (m) | (m) |
| 2014-06-30 | (m) | $1.01B | (m) | (m) |
| 2014-03-31 | (m) | $923.11M | (m) | (m) |
| 2013-12-31 | $763.25M | $872.42M | (m) | 87.49% |
| 2013-09-30 | (m) | $820.35M | (m) | (m) |
| 2013-06-30 | (m) | $763.71M | (m) | (m) |
| 2013-03-31 | (m) | $679.69M | (m) | (m) |
| 2012-12-31 | (m) | $585.98M | (m) | (m) |
| 2012-09-30 | (m) | $485.81M | (m) | (m) |
| 2012-06-30 | (m) | $394.78M | (m) | (m) |
| 2012-03-31 | (m) | $329.81M | (m) | (m) |
| 2011-12-31 | $252.58M | $272.28M | (m) | 92.76% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | $172.14M | $189.49M | (m) | 90.84% |
| 2010-12-31 | $156.45M | $173.78M | (m) | 90.03% |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $128.45M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |